Vitamin supplementation reduces blood homocysteine levels: A controlled trial in patients with venous thrombosis and healthy volunteers

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 3, 1998, Pages 356-361

  Heijer, Martin Den ^a,c   Brouwer, Ingeborg A ^a   Bos, Gerard M J ^b   Blom, Henk J ^c   Van Der Put, Nathalie M J ^c   Spaans, Anja P ^a   Rosendaal, Frits R ^d   Thomas, Chris M G ^c   Haak, Hans L ^a   Wijermans, Pierre W ^a   Gerrits, Wim B J ^a  

^a LEYENBURG HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Folate; Homocysteine; MTHFR; Venous thrombosis; Vitamin supplementation

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HOMOCYSTEINE; HYDROXOCOBALAMIN; PYRIDOXINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; VEIN THROMBOSIS; VITAMIN BLOOD LEVEL; VITAMIN INTAKE;

EID: 17344370074     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.atv.18.3.356     Document Type: Article

References (28)

1. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RB, Jr. ed. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. New York/Basel/Hong Kong: Marcel Dekker Inc; 1993:183-236.
2. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res. 1993;71: 337-359.
3. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274: 1049-1057.
4. den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet. 1995;345:882-885.
5. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
6. Brattström LE, Hultberg BL, Hardebo JE. Folic acid responsive postmenopausal homocysteinemia. Metabolism. 1985;34:1073-1077.
7. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism. 1988; 37:697-701.
8. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM, Kloppenborg PWC. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb. 1994;14:465-470.
9. van den Berg M, Franken DG, Boers GHJ, Blom HJ, Jakobs C, Stehouwer CDA, Rauswerda JA. Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vasc Surg. 1994;20:933-940.
10. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr. 1994;124:1927-1933.
11. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet. 1995;346: 85-89.
12. Schrijver J, Speek AJ, Schreurs WHP. Semi-automated fluorometric determination of pyridoxal-5′-phosphate (vitamin B6) in whole blood by high-performance liquid chromatography (HPLC). Int J Vitam Nutr Res. 1981; 51:216-222.
13. Steegers-Theunissen RPM, Boers GHJ, Steegers EAP, Trijbels FJM, Thomas CMG, Eskes TKAB. Effects of sub-50 oral contraceptives on homocysteine metabolism: a preliminary study. Contraception. 1992;45: 129-139.
14. Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem. 1993;39:263-271.
15. te Poele-Pothoff MTWB, van der Berg M, Franken DG, Boers GHJ, Jacobs C, de Kroon IFI, Eskes TAKE, Trijbels JMF, Blom HJ. Three different methods for the determination of tal homocysteine in plasma. Ann Clin Biochem. 1995;32:218-220.
16. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers, GHJ, den Heijer M, Kluytmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylene-tetrahydrotblate reductase. Nat Genet. 1995;10:111-113.
17. Ubbink JB, Vermaak WJH, Bennett JM, Becker PJ, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemias in angiographically defined coronary heart disease. Klin Wochenschr. 1991; 69:527-534.
18. Selhub J, Jaques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
19. Lederle FA. Oral cobalamin for pernicious anemia: medicine's best kept secret? JAMA. 1991;265:94-95.
20. Parry GJ, Bredensen DE. Sensory neuropathy with low dose pyridoxine. Neurology. 1985;35:1466-1468.
21. Schaumberg H, Kaplan J, Windebanke A, Vick N, Rasmus S, Pleasure D, Brown MJ. Sensory neuropathy from pyridoxine abuse. N Engl J Med. 1983;309:445-448.
22. Engbertsen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ. Thermolabile 5,10-methyIenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995;56:142-150.
23. Kluytmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, den Heijer M, Trijbels FJM, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
24. Kluytmans LAJ, Kastelein JJP, Lindemans J, Boers GHJ, Heil SG, Bruschke AVG, Jukema JW, van den Heuvel LPWJ, Trijbels JMF, Boerma GJM, Verheugt FWA, Willems F, Blom HJ. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1997;96:2573-2577.
25. Kluytmans LAJ, den Heijer M, Reitsma PH, Heil SH, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost. In press.
26. Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, Block PC, Holzgang, Anderson PH, Seltzer D, Upson B, Lin QR. The effects of folic acid supplementation on plasma tal homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 1997;17:1157-1162.
27. Stampfer MJ, Rimm EB. Folate and cardiovascular disease: why we need a trial now. JAMA. 1996;275:1929-1930.
28. den Heijer M, Bos GMJ, Gerrits WBJ, Blom HJ. Will a decrease of blood homocysteine by vitamin supplementation reduce the risk for vascular disease? Fibrinolysis. 1994;8(suppl 2):91-92.